This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

BioMarin accuses rivals of stockpiling infringing medication in complaint to USITC

By Nick Robertson ( April 3, 2025, 22:04 GMT | Insight) -- BioMarin Pharmaceutical filed a complaint at the US International Trade Commission accusing Ascendis Pharma and Wacker Biotech of importing illegal quantities of C-type natriuretic peptides into the US in preparation for the FDA approval of a rival drug to BioMarin’s Voxzogo. BioMarin is seeking an exclusion order, arguing that the companies are attempting to undermine Voxzogo’s market and infringing its patent.California-based BioMarin Pharmaceutical filed a complaint at the US International Trade Commission Tuesday alleging that two European rivals — Danish Ascendis Pharma and German Wacker Biotech — have imported illegal quantities of a drug and drug components covered by its patent, in an attempt to launch a rival medication....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections